EPCAM and ovarian cancer: The bispecific CD44-EpCAM aptamer was significantly more effective than either single CD44 or EpCAM aptamer for inhibiting the cells growth or inducing apoptosis in ovarian cancer cells both in vitro and in vivo studies [178].